23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
20:15 , Feb 16, 2017 |  BC Week In Review  |  Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...
07:00 , Jun 30, 2016 |  BC Innovations  |  Targets & Mechanisms

AChE revisited

Selina Koch and Mark Zipkin, Staff Writers  Neuro-Bio Ltd. has identified a peptide derived from AChE - the enzyme responsible for breaking down acetylcholine - and believes the fragment is the main pathological driver in Alzheimer's...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

Dexmecamylamine: Development discontinued

Targacept discontinued development of TC-5214 to treat OAB after top-line data from a double-blind, U.S. Phase IIb trial in 768 patients with OAB “were not compelling enough to justify the compound’s continued development.” Twice-daily 2...
00:26 , Jul 29, 2014 |  BC Extra  |  Clinical News

Targacept slides after hours on OAB setback

Targacept Inc. (NASDAQ:TRGT) slid $0.94 (24%) to $3.92 in early after-hours trading on Monday after the company said it was discontinuing development of dexmecamylamine ( TC-5214). Targacept said after market close that top-line data from...
23:28 , Jul 14, 2014 |  BC Extra  |  Clinical News

Targacept drops TC-1734, continues trimming pipeline

Targacept Inc. (NASDAQ:TRGT) discontinued development of TC-1734 after the compound missed the co-primary endpoints of improving cognitive and global function from baseline to week 52 vs. donepezil in a 293-patient Phase IIb trial to treat...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Dexmecamylamine: Completed Phase IIb enrollment

Targacept completed enrollment of about 750 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 0.5, 1 or 2 mg oral TC-5214 twice daily for 12 weeks (see BioCentury, June 10, 2013). Targacept Inc....
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

TC-5619: Development discontinued

Targacept discontinued development of TC-5619 to treat negative symptoms and cognitive dysfunction in patients with schizophrenia after top-line data from a double-blind, international Phase IIb trial in 477 patients with schizophrenia showed that once-daily 5...
00:49 , Dec 17, 2013 |  BC Extra  |  Clinical News

Targacept falls after discontinuing TC-5619 for schizophrenia, AD

Targacept Inc. (NASDAQ:TRGT) fell $1.95 (33%) to $4 in early after-hours trading late Monday after announcing that it discontinued development of TC-5619 to treat negative symptoms and cognitive dysfunction in patients with schizophrenia after the...
08:00 , Nov 18, 2013 |  BioCentury  |  Strategy

BMS reaches pivot point

Bristol-Myers Squibb Co. isn't talking publicly about narrowing its focus by dropping discovery in several crowded and/or particularly difficult disease areas while doubling down on others like cancer immunotherapy. Nevertheless, the decision looks to be...